Hepalink-Backed HighTide Bets On NASH For Global Markets
Executive Summary
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
You may also be interested in...
Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Intercept Retakes The Lead In NASH
A week after Gilead missed its primary endpoint in the first Phase III NASH trial, Intercept shows a statistically significant fibrosis benefit in Phase III with OCA. It plans to file for approval later this year.
Shenzhen Hepalink Acquires U.S. API Manufacturer Scientific Protein Laboratories
Shenzhen Hepalink Pharmaceutical acquired 100% of the equity interest of Scientific Protein Laboratories (SLP), a U.S. leading manufacturer of heparin active pharmaceutical ingredients (APIs) for $2.075 billion Jan. 13.
Need a specific report? 1000+ reports available
Buy Reports